The present invention is based on the fusion of FimH, CsgA and PapG adhesins (type 1 Fimbriae, curli and P, respectively) to generate biomolecules that can be used as vaccines against UTIs. Briefly, the invention is based on the design of a fusion template gene fimH-csgA-papG-fimH-csgA and defined as fcpfc to generate the different combinations of monomeric [FimH, CsgA and PapG], dimeric [FimH-CsgA (FC), CsgA-PapG (CP) and PapG-FimH (PF)] and trimeric (FimH-PapG-CsgA (FCP), PapG-CsgA-FimH (PCF) and CsgA-FimH-PapG (CFP)] proteins. Bioactivity was determined by the antibodies present in UP sera and urine, the quantification in the release of cytokines and adhesion inhibition assays.